According to a new report Asia Pacific Contrast Media Market, published by KBV Research, the Asia Pacific Contrast Media Market would witness market growth of 4.9% CAGR during the forecast period (2019-2025).
The China market dominated the Asia Pacific MRI Market by Country in 2018, and would continue to be a dominant market till 2025. The Japan market is anticipated to grow at a CAGR of 6.4% during (2019 - 2025). Additionally, The India market is experiencing a market growth rate of 6.4% during (2019 - 2025).
The Iodinated market dominated the South Korea Contrast Media Market by Product Type in 2018, growing at a CAGR of 5.1 % during the forecast period. The Gadolinium-based market is expected to witness a CAGR of 4.9% during (2019 - 2025).
The Neurological disorders market dominated the Singapore Contrast Media Market by Application in 2018, thereby, achieving a market value of $22 million by 2025. The Cancer market is witnessing a CAGR of 6.1% during (2019 - 2025). The Musculoskeletal disorders market is poised to grow at a CAGR of 5.57% during (2019 - 2025).
Structural Insights: https://www.kbvresearch.com/asia-pacific-contrast-media-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG, General Electric (GE) Co. (GE Healthcare), The Guerbet Group, Lantheus Holdings, Inc., Bracco S.p.A., Trivitron Healthcare Pvt. Ltd., Nano Therapeutics Pvt. Ltd., Magnus Health, LLC (Veracross LLC), Imax Diagnostic Imaging Limited, and Daiichi Sankyo Company, Limited.
By Product Type
By Application
By Modality
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
